NASDAQ
0.50USD
-0.04 (-7.30%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
17.6M
P/E
—
EPS
—
Beta
2.99
52W range
0.276-4.99
Day range
0.47–0.88
Open
0.86
Prev close
0.54
Volume
1.3M
Avg volume
175.7K
Dividend
0.00
IPO
2015-01-06
https://www.benzinga.com/trading-ideas/movers/26/08/61239591/why-hive-digital-technologies-shares-are-trading-higher-by-over-8-here-are-20-stocks-moving-premarket · 8/17/2026+0.60
https://www.globenewswire.com/news-release/2026/05/11/3292287/0/en/Skye-Bioscience-Reports-First-Quarter-2026-Financial-Results-and-Business-Update.html · 5/11/2026+0.60
https://www.globenewswire.com/news-release/2026/01/15/3219784/0/en/SKYE-Investors-Have-Opportunity-to-Lead-Skye-Bioscience-Inc-Securities-Fraud-Lawsuit-with-the-Schall-Law-Firm.html · 1/15/2026-1.00
https://www.prnewswire.com/news-releases/skye-bioscience-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-january-16-2026-to-discuss-your-rights--skye-302655818.html · 1/8/2026-1.00
https://www.prnewswire.com/news-releases/skye-investors-have-opportunity-to-lead-skye-bioscience-inc-securities-fraud-lawsuit-302654378.html · 1/7/2026-1.00
https://www.globenewswire.com/news-release/2026/01/01/3212012/9788/en/Bronstein-Gewirtz-Grossman-LLC-Urges-Skye-Bioscience-Inc-Investors-to-Act-Class-Action-Filed-Alleging-Investor-Harm.html · 1/1/2026-1.00
https://www.globenewswire.com/news-release/2026/01/01/3212004/0/en/SKYE-Investors-Have-Opportunity-to-Lead-Skye-Bioscience-Inc-Securities-Fraud-Lawsuit-with-the-Schall-Law-Firm.html · 1/1/2026-1.00
https://www.newsfilecorp.com/release/278628/DEADLINE-ALERT-Faruqi-Faruqi-LLP-Investigates-Claims-on-Behalf-of-Investors-of-Skye-Bioscience · 12/28/2025-1.00
https://www.prnewswire.com/news-releases/shareholder-action-notice-faruqi--faruqi-llp-investigates-claims-on-behalf-of-investors-of-skye-bioscience-302647589.html · 12/23/2025-1.00
https://www.globenewswire.com/news-release/2025/12/19/3208741/673/en/ROSEN-TOP-RANKED-INVESTOR-COUNSEL-Encourages-Skye-Bioscience-Inc-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-SKYE.html · 12/19/2025-1.00
https://www.globenewswire.com/news-release/2025/12/15/3205656/0/en/Portnoy-Law-Firm-Announces-Class-Action-on-Behalf-of-Skye-Bioscience-Inc-Investors.html · 12/15/2025-1.00
https://www.newsfilecorp.com/release/277786/SHAREHOLDER-ACTION-REMINDER-Faruqi-Faruqi-LLP-Investigates-Claims-on-Behalf-of-Investors-of-Skye-Bioscience · 12/13/2025-1.00
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
